An inability to distinguish between CIDP and POEMS syndrome can negatively affect treatment strategies and outcomes. A 2-step protocol using conduction block and maximum/minimum cross-sectional area ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disease that damages and destroys the nerves in a person’s body. CIDP affects a person’s ability to move, especially ...

New research may redefine how chronic inflammatory demyelinating polyneuropathy is diagnosed. The study may help doctors more effectively diagnose and treat CIDP. New research from Jefferson Hospital ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) may be a rare disease, but it is one of the most common forms of neuropathy and the most common form of chronic autoimmune neuropathy. Roughly ...

Discovery of the antigenic targets associated with nerve-specific autoimmune diseases is a crucial step in understanding their pathogenesis The identification of highly disease-specific autoantibodies ...

This week, we are going to continue down the road of autoimmune peripheral nerve conditions to discuss two that we have touched on in the past—Guillain-Barré Syndrome and CIDP (chronic inflammatory ...

Kieseier and colleagues present a review of the literature on immune-mediated neuropathies, emphasizing the immunopathologic mechanisms underlying these neuropathies. Immune-mediated neuropathies have ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...

The PATH study demonstrated that the percentage of patients experiencing CIDP relapse or withdrawal for any other reason during SCIg treatment was significantly lower with Hizentra CSL Behring ...